ACTG 347 - 141W94/VX-478 is an investigational drug under development by Glaxo, Inc. This study is proposed to test the hypothesis that monotherapy with 141W94/VX-478 doses that result in C min levels far in excess of the IC90 corrected for plasma protein binding for HIV-1 can achieve the same virological and immunological effects in terms of magnitude and durability as has been observed with combinations of other protease inhibitors plus nucleoside analogs.
Showing the most recent 10 out of 782 publications